These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 27485386)

  • 1. New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms.
    Spurr SS; Bayle ED; Yu W; Li F; Tempel W; Vedadi M; Schapira M; Fish PV
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4518-4522. PubMed ID: 27485386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
    Zhu B; Zhang H; Pan S; Wang C; Ge J; Lee JS; Yao SQ
    Chemistry; 2016 Jun; 22(23):7824-36. PubMed ID: 27115831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
    Yao Y; Chen P; Diao J; Cheng G; Deng L; Anglin JL; Prasad BV; Song Y
    J Am Chem Soc; 2011 Oct; 133(42):16746-9. PubMed ID: 21936531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.
    Yu W; Smil D; Li F; Tempel W; Fedorov O; Nguyen KT; Bolshan Y; Al-Awar R; Knapp S; Arrowsmith CH; Vedadi M; Brown PJ; Schapira M
    Bioorg Med Chem; 2013 Apr; 21(7):1787-1794. PubMed ID: 23433670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel DOT1L ReceptorNatural Inhibitors Involved in Mixed Lineage Leukemia: a Virtual Screening, Molecular Docking and Dynamics Simulation Study.
    Raj U; Kumar H; Gupta S; Varadwaj PK
    Asian Pac J Cancer Prev; 2015; 16(9):3817-25. PubMed ID: 25987043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
    Anglin JL; Deng L; Yao Y; Cai G; Liu Z; Jiang H; Cheng G; Chen P; Dong S; Song Y
    J Med Chem; 2012 Sep; 55(18):8066-74. PubMed ID: 22924785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-guided DOT1L probe optimization by label-free ligand displacement.
    Yi JS; Federation AJ; Qi J; Dhe-Paganon S; Hadler M; Xu X; St Pierre R; Varca AC; Wu L; Marineau JJ; Smith WB; Souza A; Chory EJ; Armstrong SA; Bradner JE
    ACS Chem Biol; 2015 Mar; 10(3):667-74. PubMed ID: 25397901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent DOT1L inhibitors by AlphaLISA based High Throughput Screening assay.
    Song Y; Li L; Chen Y; Liu J; Xiao S; Lian F; Zhang N; Ding H; Zhang Y; Chen K; Jiang H; Zhang C; Liu YC; Chen S; Luo C
    Bioorg Med Chem; 2018 May; 26(8):1751-1758. PubMed ID: 29534934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
    Basavapathruni A; Jin L; Daigle SR; Majer CR; Therkelsen CA; Wigle TJ; Kuntz KW; Chesworth R; Pollock RM; Scott MP; Moyer MP; Richon VM; Copeland RA; Olhava EJ
    Chem Biol Drug Des; 2012 Dec; 80(6):971-80. PubMed ID: 22978415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibitors of protein methyltransferases.
    Kaniskan HÜ; Konze KD; Jin J
    J Med Chem; 2015 Feb; 58(4):1596-629. PubMed ID: 25406853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library.
    Gibbons GS; Chakraborty A; Grigsby SM; Umeano AC; Liao C; Moukha-Chafiq O; Pathak V; Mathew B; Lee YT; Dou Y; Schürer SC; Reynolds RC; Snowden TS; Nikolovska-Coleska Z
    Eur J Med Chem; 2020 Mar; 189():112023. PubMed ID: 31978781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disruptor of telomeric silencing 1-like (DOT1L): disclosing a new class of non-nucleoside inhibitors by means of ligand-based and structure-based approaches.
    Sabatino M; Rotili D; Patsilinakos A; Forgione M; Tomaselli D; Alby F; Arimondo PB; Mai A; Ragno R
    J Comput Aided Mol Des; 2018 Mar; 32(3):435-458. PubMed ID: 29335872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and anti leukemia cells proliferation activities of pyrimidylaminoquinoline derivatives as DOT1L inhibitors.
    Zhang L; Chen Y; Liu N; Li L; Xiao S; Li X; Chen K; Luo C; Chen S; Chen H
    Bioorg Chem; 2018 Oct; 80():649-654. PubMed ID: 30059890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of phenoxyacetamide derivatives as novel DOT1L inhibitors via docking screening and molecular dynamics simulation.
    Luo M; Wang H; Zou Y; Zhang S; Xiao J; Jiang G; Zhang Y; Lai Y
    J Mol Graph Model; 2016 Jul; 68():128-139. PubMed ID: 27434826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of 5'-deoxy-5'-amino-5'-C-methyl adenosine derivatives and their activity against DOT1L.
    Liu T; Xie W; Li C; Ren H; Mao Y; Chen G; Cheng M; Zhao D; Shen J; Li J; Zhou Y; Xiong B; Chen YL
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4960-4963. PubMed ID: 29050780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Novel Disruptor of Silencing Telomeric 1-Like (DOT1L) Inhibitors using a Target-Specific Scoring Function for the (S)-Adenosyl-l-methionine (SAM)-Dependent Methyltransferase Family.
    Wang Y; Li L; Zhang B; Xing J; Chen S; Wan W; Song Y; Jiang H; Jiang H; Luo C; Zheng M
    J Med Chem; 2017 Mar; 60(5):2026-2036. PubMed ID: 28165739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development.
    Rogawski DS; Grembecka J; Cierpicki T
    Future Med Chem; 2016 Sep; 8(13):1589-607. PubMed ID: 27548565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
    Yu W; Chory EJ; Wernimont AK; Tempel W; Scopton A; Federation A; Marineau JJ; Qi J; Barsyte-Lovejoy D; Yi J; Marcellus R; Iacob RE; Engen JR; Griffin C; Aman A; Wienholds E; Li F; Pineda J; Estiu G; Shatseva T; Hajian T; Al-Awar R; Dick JE; Vedadi M; Brown PJ; Arrowsmith CH; Bradner JE; Schapira M
    Nat Commun; 2012; 3():1288. PubMed ID: 23250418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
    Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
    ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Novel Disruptor of Telomeric Silencing 1-like (DOT1L) Inhibitors through Structure-Based Virtual Screening and Biological Assays.
    Chen S; Li L; Chen Y; Hu J; Liu J; Liu YC; Liu R; Zhang Y; Meng F; Zhu K; Lu J; Zheng M; Chen K; Zhang J; Jiang H; Yao Z; Luo C
    J Chem Inf Model; 2016 Mar; 56(3):527-34. PubMed ID: 26914852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.